Firehawk®
Features
Adopted the platform of TES Technology®.
Coating exposed area is only 5% of the stent surface.
Drug in-vivo released over 90 days.
Polymer fully absorbed in 9 months.
Average Metal Coverage Rate14.0-16.1%
World's lowest drug dosage stent.
Coating exposed area is only 5% of the stent surface.
Drug in-vivo released over 90 days.
Polymer fully absorbed in 9 months.
Average Metal Coverage Rate14.0-16.1%
World's lowest drug dosage stent.
Description
Firehawk® Rapamycin Target Eluting Coronary Stent System is the World's First and Only Target Eluting Stent (TES), which is the new generation product of Shanghai MicroPort Medical (Group) Co., Ltd. following the Firebird and Firebird2 stent to treat coronary artery stenosis or occlusion disease.
